On March 14, 2007, the Centers for Medicare & Medicaid Services (CMS) announced that it is reviewing its Erythropoiesis (EPO) monitoring policy for end-stage renal disease (ESRD) patients who are dialyzed in renal facilities. EPO is used to stimulate blood cell production in ESRD patients. The Medicare benefit policy is consistent with the National Kidney Foundation and industry guidelines to maintain a target hemoglobin level in the range of 10 g/dl to 12 g/dl (or hematocrit level of 30 to 36 percent). Under the current EPO monitoring policy, unless the provider includes information with the claim that the dosage already has been reduced, CMS will initiate a payment reduction if the hemoglobin exceeds 13 g/dl (or hematocrit level of 39 percent).
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
